中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

987 records (took 0.044 seconds)

    NUCLEIC ACID CONSTRUCT SYSTEMS CAPABLE OF DIAGNOSING OR TREATING A CELL STATE
    183.
    发明申请
    NUCLEIC ACID CONSTRUCT SYSTEMS CAPABLE OF DIAGNOSING OR TREATING A CELL STATE 审中-公开
    可诊断或治疗细胞状态的核酸构建体系

    公开(公告)号：US20130260386A1

    公开(公告)日：2013-10-03

    申请号：US13914686

    申请日：2013-06-11

    Applicant: Yeda Research and Development Co., Ltd.

    Inventor： Lior NISSIM ,  Roy Bar-Ziv

    IPC: C12Q1/68

    CPC classification number: C12Q1/6897 ,  C12N15/1055 ,  C12N15/85 ,  C12N2830/007 ,  C12N2830/008 ,  G01N33/5008 ,  G01N33/5091

    Abstract: Nucleic acid construct systems are disclosed capable of diagnosing and treating a cell state (e.g. disease state). Methods of diagnosing and treating disease states using the nucleic acid constructs described herein are also disclosed. In addition, methods of screening for agents capable of reversing a disease phenotype using the nucleic acid constructs of the present invention are disclosed.

    Abstract translation: 公开了能够诊断和治疗细胞状态（例如疾病状态）的核酸构建系统。 还公开了使用本文所述的核酸构建体诊断和治疗疾病状态的方法。 此外，公开了使用本发明的核酸构建体筛选能够逆转疾病表型的试剂的方法。

    TNF receptor-specific antibodies
    185.
    发明申请
    TNF receptor-specific antibodies 审中-公开
    TNF受体特异性抗体

    公开(公告)号：US20030228312A1

    公开(公告)日：2003-12-11

    申请号：US10423927

    申请日：2003-04-28

    Applicant: Yeda Research and Development Co. Ltd

    Inventor： David Wallach ,  Jacek Bigda ,  Igor Beletsky ,  Igor Mett ,  Hartmut Engelmann

    IPC: A61K039/395 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06 ,  C07K016/24

    CPC classification number: C07K16/2866 ,  A61K38/00 ,  C07K14/7151 ,  C07K16/4258 ,  C07K2319/00

    Abstract: Antibodies to Tumor Necrosis Factor receptors (TNF-Rs) which inhibit the cytocidal effect of TNF but not its binding to the TNF-Rs, and ligands interacting with other receptors of the TNF/NGF family, are provided together with methods of producing them. The antibodies preferably bind to the fourth cysteine rich domain of the p75 TNF receptor or to the region between said fourth cysteine rich domain and the cell membrane.

    Abstract translation: 与TNF-NGF家族的其他受体相互作用的配体，抑制肿瘤坏死因子的杀细胞活性而不是与TNF-R结合的肿瘤坏死因子受体（TNF-Rs）的抗体与生产它们的方法一起提供。 抗体优选结合p75 TNF受体的第四半胱氨酸富集结构域或所述第四富含半胱氨酸的结构域与细胞膜之间的区域。

    Immunogenic compositions for induction of anti-tumor immunity
    186.
    发明申请
    Immunogenic compositions for induction of anti-tumor immunity 失效
    用于诱导抗肿瘤免疫的免疫原性组合物

    公开(公告)号：US20020197270A1

    公开(公告)日：2002-12-26

    申请号：US10032482

    申请日：2002-01-02

    Applicant: Yeda Research and Development Co. Ltd.

    Inventor： Irun R. Cohen ,  Varda Rotter ,  Roland Wolkowicz ,  Pedro Ruiz ,  Neta Erez-Alon ,  Johannes Herkel

    IPC: A61K048/00 ,  A61K039/00

    CPC classification number: C07K16/30 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/51 ,  C07K16/18 ,  C07K2317/565 ,  C07K2317/73

    Abstract: The invention relates to the use of an immunogen selected from the group consisting of (i) an anti-p53 mAb; (ii) a fragment of an anti-p53 mAb; (iii) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (iv) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle, for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed.

    Abstract translation: 本发明涉及选自以下的免疫原的用途：（i）抗p53 mAb; （ii）抗p53 mAb的片段; （iii）基于抗p53 mAb的重链或轻链的CDR的肽，该肽能够引发针对p53的抗体; 和（iv）编码合适的基因递送载体中抗p53mAb的可变（V）区的DNA分子，用于制备用于诱导哺乳动物抗肿瘤免疫的药物组合物，用于激活增强的 对哺乳动物中p53分子的免疫应答，和/或用于诱导哺乳动物中突变​​和野生型形式的p53的免疫应答。 公开了使用抗p53 mAb和基于不同抗p53 mAb的轻链的CDR2和CDR3的CDR3和新型肽。

    Optical resonators with orthogonally polarized modes
    187.
    发明申请
    Optical resonators with orthogonally polarized modes 失效
    具有正交偏振模式的光学谐振器

    公开(公告)号：US20020154672A1

    公开(公告)日：2002-10-24

    申请号：US10099473

    申请日：2002-03-15

    Applicant: Yeda Research and Development Co. Ltd.

    Inventor： Asher A. Friesem ,  Shmuel Blit ,  Ram Oron ,  Erez Hasman ,  Nir Davidson

    IPC: H01S003/08

    CPC classification number: H01S3/08036 ,  H01S3/08054 ,  H01S3/082 ,  H01S3/106 ,  H01S2301/20 ,  H01S2301/203

    Abstract: An optical resonator supporting two sets of simultaneously co-existent oscillation modes (30 and 31), having polarizations orthogonal to each other. Mode control elements (28 and 29), such as apertures and phase elements, are introduced into the resonator to allow only preferred modes to exist. The placement and orientation of the sets are designed such that the high intensity zones of one set fall on the nodes or low intensity zones of the other set in an interlaced pattern. Thus, in a laser resonator, better utilization of the gain medium (24) is achieved and the beam quality and brightness over multimode lasing are improved. This configuration improves the performance of high Fresnel number resonators, in both pulsed and continuous lasers, for applications such as scribing, drilling, cutting, target designation and rangefinding. An application of the intra-cavity coherent summation of orthogonally polarized modes is described, whereby azimuthally or radially polarized beams may be obtained.

    Abstract translation: 支持两组同时共存的振荡模式（30和31）的光学谐振器，具有彼此正交的极化。 将模式控制元件（28和29）（诸如孔径和相位元件）引入到谐振器中，以仅允许存在优选的模式。 这些组的放置和取向被设计成使得一组的高强度区域以交错图案落在另一组的节点或低强度区域上。 因此，在激光谐振器中，实现了增益介质（24）的更好的利用，并提高了多模激光的光束质量和亮度。 这种配置提高了脉冲和连续激光器中高菲涅尔数谐振器的性能，适用于诸如划线，钻孔，切割，目标指定和测距等应用。 描述了正交偏振模式的腔内相干求和的应用，由此可以获得方位角或径向偏振光束。

    Acousto-optic scanning system with fast non-linear scan
    188.
    发明申请
    Acousto-optic scanning system with fast non-linear scan 有权
    具有快速非线性扫描功能的声光扫描系统

    公开(公告)号：US20020141035A1

    公开(公告)日：2002-10-03

    申请号：US10021903

    申请日：2001-12-13

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

    Inventor： Nir Davidson ,  Nir Friedman ,  Ariel Kaplan

    IPC: G02F001/11

    CPC classification number: G02F1/33

    Abstract: An acousto-optic scanning system, which relies on two counter propagating acoustic waves with the same frequency modulation. This scheme completely suppresses the linear frequency chirp, and thus enables the generation of fast non-linear scans and non-constant linear scans. By changing the phase between the modulating signals, this scheme also provides fast longitudinal scans of the focal point.

    Abstract translation: 一种声光扫描系统，其依赖于具有相同频率调制的两个反传播声波。 该方案完全抑制线性频率啁啾，从而能够产生快速非线性扫描和非恒定线性扫描。 通过改变调制信号之间的相位，该方案还提供焦点的快速纵向扫描。

    GLYCOALKALOID METABOLISM ENYZYMES (GAMES) AND USES THEREOF
    190.
    发明申请
    GLYCOALKALOID METABOLISM ENYZYMES (GAMES) AND USES THEREOF 有权

    公开(公告)号：US20250092415A1

    公开(公告)日：2025-03-20

    申请号：US18910862

    申请日：2024-10-09

    Applicant: Yeda Research and Development Co. Ltd. ,  Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.

    Inventor： Asaph AHARONI ,  Prashant SONAWANE ,  Pablo D. CARDENAS ,  Saul BURDMAN

    IPC: C12N15/82 ,  C12N9/02 ,  C12N9/04

    Abstract: Disclosed herein are genetically modified plants having altered biological activity of 3-β-hydroxysteroid dehydrogenase/isomerase (GAME25), or 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plants have an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof. Further disclosed herein are genetically modified plants having altered expression of a gene encoding a 3-β-hydroxysteroid dehydrogenase/isomerase (GAME25), or a 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plant has an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof. Methods of producing these genetically modified plants are also disclosed.

Patent Agency Ranking